Page last updated: 2024-11-05
trimethoprim and Preterm Birth
trimethoprim has been researched along with Preterm Birth in 1 studies
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.
trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Our exploratory analyses support the hypothesis that IRS may significantly reduce malaria and preterm birth risk among pregnant women with HIV receiving bed nets, daily trimethoprim-sulfamethoxazole, and combination antiretroviral therapy." | 5.24 | Protective Effect of Indoor Residual Spraying of Insecticide on Preterm Birth Among Pregnant Women With HIV Infection in Uganda: A Secondary Data Analysis. ( Awori, P; Clark, TD; Cohan, D; Dorsey, G; Gosling, R; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Koss, CA; Muhindo, M; Nakalambe, M; Natureeba, P; Ochieng, T; Plenty, A; Roh, ME; Shiboski, S, 2017) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Roh, ME | 1 |
| Shiboski, S | 1 |
| Natureeba, P | 1 |
| Kakuru, A | 1 |
| Muhindo, M | 1 |
| Ochieng, T | 1 |
| Plenty, A | 1 |
| Koss, CA | 1 |
| Clark, TD | 1 |
| Awori, P | 1 |
| Nakalambe, M | 1 |
| Cohan, D | 1 |
| Jagannathan, P | 1 |
| Gosling, R | 1 |
| Havlir, DV | 1 |
| Kamya, MR | 1 |
| Dorsey, G | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE Birth Cohort 2)[NCT02282293] | Phase 3 | 200 participants (Actual) | Interventional | 2014-12-09 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Composite Adverse Birth Outcome (Proportion With Low Birth Weight (<2500 gm), Spontaneous Abortion (<28 Weeks), Stillbirth (Fetal Demise ≥28 Weeks), Congenital Anomaly, or Preterm Delivery (<37 Weeks)
Proportion with low birth weight (<2500 gm), spontaneous abortion (<28 weeks), stillbirth (fetal demise ≥28 weeks), congenital anomaly, or preterm delivery (<37 weeks) (NCT02282293)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|
| TS + DP Placebo Pregnancy | 15 |
| Daily TS + Monthly DP Pregnancy | 20 |
Incidence of Malaria, Pregnant Women
The primary outcome will be the incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. (NCT02282293)
Timeframe: Time at risk will begin following administration of first dose of study drug to delivery
| Intervention | Events per person-year (Number) |
|---|
| TS + DP Placebo Pregnancy | 0.03 |
| Daily TS + Monthly DP Pregnancy | 0.00 |
Number of Monthly Routine Visits With Positive Blood Samples for Parasites
Proportion of monthly routine blood samples positive by LAMP for parasites (NCT02282293)
Timeframe: Following administration of first dose of study drug to delivery
| Intervention | visits with positive blood sample (Count of Units) |
|---|
| TS + DP Placebo Pregnancy | 12 |
| Daily TS + Monthly DP Pregnancy | 5 |
Number of Participants With Placental Malaria
The primary outcome will be the prevalence of placental malaria based on placental histopathology and dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence of placental infection. (NCT02282293)
Timeframe: at delivery estimated to be within 10 to 30 weeks of study entry
| Intervention | Participants (Count of Participants) |
|---|
| TS + DP Placebo Pregnancy | 3 |
| Daily TS + Monthly DP Pregnancy | 6 |
Number of Routine Visits Measured Every 8 Weeks During Pregnancy for Which the Participants Had Anemia
Anemia (hemoglobin less than 11g/dL) measured every 8 weeks during pregnancy (NCT02282293)
Timeframe: Following administration of first dose of study drugs to delivery
| Intervention | Routine visit done every 8 weeks (Count of Units) |
|---|
| TS + DP Placebo Pregnancy | 65 |
| Daily TS + Monthly DP Pregnancy | 51 |
Maternal Parasitemia at Delivery by Microscopy and LAMP
Proportion of women with parasitemia detected by microscopy or LAMP at delivery (NCT02282293)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|
| Microscopy | LAMP |
|---|
| Daily TS + Monthly DP Pregnancy | 1 | 4 |
,| TS + DP Placebo Pregnancy | 0 | 2 |
Placental Parasitemia (Number of Women With Placental Blood Samples Positive for Malaria by Microscopy or PCR)
Proportion of placental blood samples positive for malaria by microscopy or PCR (NCT02282293)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|
| Microscopy of placental blood | LAMP analysis of placental blood |
|---|
| Daily TS + Monthly DP Pregnancy | 1 | 3 |
,| TS + DP Placebo Pregnancy | 0 | 1 |
Trials
1 trial available for trimethoprim and Preterm Birth